Logo

Siga’s Tpoxx (tecovirimat) Receives the US FDA’s Approval for the Treatment of Small Pox

Share this

Siga’s Tpoxx (tecovirimat) Receives the US FDA’s Approval for the Treatment of Small Pox

Shots:

  • The US FDA has approved Tpoxx as an IV formulation for smallpox caused by the variola virus in adults & pediatric patients. The therapy provides an alternative option who are not able to swallow oral capsules of Tpoxx
  • The approval was based on animal efficacy studies in nonhuman primates & rabbits infected with nonvariola orthopoxviruses that were adequate & well-controlled
  • Tpoxx is a novel small-molecule drug that prevents the formation of secondary viral envelopes in the variola virus and other poxviruses, thereby inhibiting viral maturation. The therapy has been approved in the US, Canada & EU for smallpox & is also indicated to treat monkeypox, cowpox & complications from immunization with vaccinia in the EU

Ref: Globe Newswire | Image: Siga 

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions